Maze Therapeutics announced positive Phase 1 clinical results for its drug candidate MZE782 targeting metabolic disorders including phenylketonuria and chronic kidney disease. Following these encouraging data, Maze secured $150 million through a private placement to fund Phase 2 trials. This development marks a significant step for Maze as it aims to compete with established assets such as Otsuka's portfolio acquired for $800 million, signaling increased investment and innovation in metabolic disease therapies.